(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.77%.
Sutro Biopharma's earnings in 2026 is -$191,086,000.On average, 12 Wall Street analysts forecast STRO's earnings for 2026 to be -$327,681,744, with the lowest STRO earnings forecast at -$1,177,102,260, and the highest STRO earnings forecast at -$73,931,300. On average, 9 Wall Street analysts forecast STRO's earnings for 2027 to be -$230,690,506, with the lowest STRO earnings forecast at -$633,199,836, and the highest STRO earnings forecast at -$6,958,240.
In 2028, STRO is forecast to generate -$2,872,759 in earnings, with the lowest earnings forecast at -$2,760,102 and the highest earnings forecast at -$2,957,252.